Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Acute Poisoning via Consumption of “Natural Max Slimming” Capsule with Complications (Hyperpigmentation and Lower Extremity Edema)

Fazel Goudarzi 1 , Nahid Najafi 2 , * , Negar Azarpira 3 , Nasim Tavakoli 1 and Zohre Najafi 4
Authors Information
1 Ali Asghar Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Toxicology and Pharmacology, Student Research Committee, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
3 Organ Transplant Research Center, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
4 Department of Veterinary Medicine, Shahid Chamran University, Ahvaz, Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: May 2017, 12 (2); e34602
  • Published Online: August 30, 2016
  • Article Type: Case Report
  • Received: November 11, 2015
  • Revised: July 18, 2016
  • Accepted: August 3, 2016
  • DOI: 10.5812/jjnpp.34602

To Cite: Goudarzi F, Najafi N, Azarpira N, Tavakoli N, Najafi Z. Acute Poisoning via Consumption of “Natural Max Slimming” Capsule with Complications (Hyperpigmentation and Lower Extremity Edema), Jundishapur J Nat Pharm Prod. 2017 ; 12(2):e34602. doi: 10.5812/jjnpp.34602.

Copyright © 2016, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
  • 1. Yuen YP, Lai CK, Poon WT, Ng SW, Chan AY, Mak TW. Adulteration of over-the-counter slimming products with pharmaceutical analogue--an emerging threat. Hong Kong Med J. 2007; 13(3): 216-20[PubMed]
  • 2. Tang MH, Chen SP, Ng SW, Chan AY, Mak TW. Case series on a diversity of illicit weight-reducing agents: from the well known to the unexpected. Br J Clin Pharmacol. 2011; 71(2): 250-3[DOI][PubMed]
  • 3. Spring S. Public Notification: Natural Max Slimming contains hidden drug ingredients. 2015;
  • 4. Slim Forte Slimming Capsule and Slim Forte Double Power Slimming Capsules: Public Notification - Undeclared Drug Ingredient. 2011;
  • 5. Four Products Marketed as Weight Loss Supplements Contain Hidden Ingredients, FDA Warns. Over the counter and FDA. 2015;
  • 6. SLIMDIA Revolution: Public Notification - Contains Undeclared Drug Ingredient Sibutramine. 2012;
  • 7. Jung J, Hermanns-Clausen M, Weinmann W. Anorectic sibutramine detected in a Chinese herbal drug for weight loss. Forensic Sci Int. 2006; 161(2-3): 221-2[DOI][PubMed]
  • 8. Link M, Hakala KS, Wsol V, Kostiainen R, Ketola RA. Metabolite profile of sibutramine in human urine: a liquid chromatography-electrospray ionization mass spectrometric study. J Mass Spectrom. 2006; 41(9): 1171-8[DOI][PubMed]
  • 9. Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999; 33(9): 968-78[PubMed]
  • 10. Muller D, Weinmann W, Hermanns-Clausen M. Chinese slimming capsules containing sibutramine sold over the Internet: a case series. Dtsch Arztebl Int. 2009; 106(13): 218-22[DOI][PubMed]
  • 11. Vidal C, Quandte S. Identification of a sibutramine-metabolite in patient urine after intake of a "pure herbal" Chinese slimming product. Ther Drug Monit. 2006; 28(5): 690-2[DOI][PubMed]
  • 12. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000; 356(9248): 2119-25[PubMed]
  • 13. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA. 2001; 286(11): 1331-9[PubMed]
  • 14. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab. 2000; 2(2): 105-12[PubMed]
  • 15. McNulty SJ, Ur E, Williams G, Multicenter Sibutramine Study G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care. 2003; 26(1): 125-31[PubMed]
  • 16. Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev. 2000; 1(2): 127-39[PubMed]
  • 17. Taflinski T, Chojnacka J. Sibutramine-associated psychotic episode. Am J Psychiatry. 2000; 157(12): 2057-8[PubMed]
  • 18. Binkley K, Knowles SR. Sibutramine and panic attacks. Am J Psychiatry. 2002; 159(10): 1793-4[PubMed]
  • 19. Clark DW, Harrison-Woolrych M. Sibutramine may be associated with memory impairment. BMJ. 2004; 329(7478): 1316[DOI][PubMed]
  • 20. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007; 369(9555): 71-7[DOI][PubMed]
  • 21. Zannad F, Gille B, Grentzinger A, Bruntz JF, Hammadi M, Boivin JM, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J. 2002; 144(3): 508-15[PubMed]
  • 22. Gratz SR, Gamble BM, Flurer RA. Accurate mass measurement using Fourier transform ion cyclotron resonance mass spectrometry for structure elucidation of designer drug analogs of tadalafil, vardenafil and sildenafil in herbal and pharmaceutical matrices. Rapid Commun Mass Spectrom. 2006; 20(15): 2317-27[DOI][PubMed]
  • 23. Zou P, Oh SS, Hou P, Low MY, Koh HL. Simultaneous determination of synthetic phosphodiesterase-5 inhibitors found in a dietary supplement and pre-mixed bulk powders for dietary supplements using high-performance liquid chromatography with diode array detection and liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr A. 2006; 1104(1-2): 113-22[DOI][PubMed]
  • 24. Cheng HL, Tseng MC, Tsai PL, Her GR. Analysis of synthetic chemical drugs in adulterated Chinese medicines by capillary electrophoresis/electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom. 2001; 15(16): 1473-80[DOI][PubMed]
  • 25. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010; 363(10): 905-17[DOI][PubMed]
  • 26. Scheen AJ. Sibutramine on cardiovascular outcome. Diabetes Care. 2011; 34 Suppl 2-9[DOI][PubMed]
  • 27. Mathys M. Drug Interactions Associated with the Use of Antidepressant Medications. Internet Continu Educ. 2005; 9(3): 1-15
  • 28. Altabas V. Drug treatment of metabolic syndrome. Curr Clin Pharmacol. 2013; 8(3): 224-31[PubMed]
  • 29. Wong AH, Barg SS, Leung AK. Pharmacotherapy for Obesity. Recent Patents Endocr Metabol Immune Drug Discover. 2010; 4(1): 47-58
  • 30. Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009; 57: 163-70[PubMed]
  • 31. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ. 2002; 166(10): 1307-8[PubMed]
  • 32. Wiglusz MS, Cubala WJ, Nowak P, Jakuszkowiak-Wojten K, Landowski J, Krysta K. Sibutramine-associated psychotic symptoms and zolpidem-induced complex behaviours: implications for patient safety. Psychiatr Danub. 2013; 25 Suppl 2-5[PubMed]
  • 33. Karam JG, McFarlane SI. Tackling obesity: new therapeutic agents for assisted weight loss. Diabetes Metabolic Syndrome Obes Targets Ther. 2010; 3: 95
  • 34. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev. 2008; 9(4): 378-87[DOI][PubMed]
  • 35. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res. 1996; 4(3): 263-70[PubMed]
  • 36. McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs. 1998; 56(6): 1093-124[PubMed]
  • 37. Azarisman SM, Magdi YA, Noorfaizan S, Oteh M. Myocardial infarction induced by appetite suppressants in Malaysia. N Engl J Med. 2007; 357(18): 1873-4[DOI][PubMed]
  • 38. Koh HL, Woo SO. Chinese proprietary medicine in Singapore: regulatory control of toxic heavy metals and undeclared drugs. Drug Saf. 2000; 23(5): 351-62[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments